drugset / Trial / NCT00250029

Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen

NCT00250029

Completed 30 enrolled New Mexico Cancer Research Alliance
Non-randomizedSingle-groupOpen-labelTreatment

Summary

1.1 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen. 1.2 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients.

Timeline

Start
2004-04
Primary completion
2005-09
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications